Skip to content
06/15/2026
  • Biotech Tools Hub
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Merlintrader Trading Pub

Merlintrader Trading Pub

Biotech catalyst news and analysis. FDA PDUFA tracker

DISCLAIMER — Educational content only. Not financial advice. Stocks can be volatile and may cause capital loss.
Read Disclaimer
Primary Menu
  • Merlintrader
    • About Merlintrader
    • Merlintrader Blog
    • Daily Briefing
    • Daily Watchlist
    • Discord
    • Latest News
    • Small & Medium Caps
    • CHARTSWATCHER 10% OFF !
    • Disclaimer
  • Cannabis Stocks Hub 2026
    • Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
    • Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
  • Space, Defense & AI Hub 2026
    • BlackSky Technology Inc. (NYSE: $BKSY) Stock Hub
    • BigBear.ai Holdings (NYSE: $BBAI)
    • Castellum, Inc. (NYSE American: $CTM) Stock Hub
    • Intuitive Machines (Nasdaq: $LUNR) Stock Hub
    • Ondas Holdings (NASDAQ: $ONDS) Stock Hub
    • Palladyne AI Corp. (Nasdaq: $PDYN) Stock Hub
    • Planet Labs PBC (NYSE: $PL)
    • POET Technologies (NASDAQ: $POET): Company Story,
    • Red Cat Holdings (NASDAQ: $RCAT)
    • Redwire Corporation (NYSE: $RDW) Stock Hub
    • Rocket Lab Corporation (Nasdaq: $RKLB) Stock Hub
    • Satellogic Inc. (Nasdaq: $SATL)
  • Biotech Stocks Hub
    • ADMA Biologics (Nasdaq: $ADMA)
    • Agios Pharmaceuticals (Nasdaq: $AGIO) Stock Hub
    • Alpha Tau Medical Ltd. (Nasdaq: $DRTS)
    • Altimmune Inc. (Nasdaq: $ALT )
    • Aquestive Therapeutics (Nasdaq: $AQST Stock Hub.
    • Ardelyx, Inc. (Nasdaq: $ARDX) Stock Hub
    • BioCryst Pharmaceuticals (Nasdaq: $BCRX) Stock Hub
    • Capricor Therapeutics (Nasdaq: $CAPR) Stock Hub
    • Corcept Therapeutics $CORT Stock Hub
    • CorMedix Therapeutics (Nasdaq: $CRMD) Stock Hub
    • Cytokinetics, Incorporated (Nasdaq: $CYTK)
    • Fate Therapeutics (Nasdaq: $FATE): Stock Hub
    • Geron Corporation (Nasdaq: $GERN) Stock Hub
    • ImmunityBio, Inc. (Nasdaq: $IBRX) Stock Hub
    • Iovance Biotherapeutics (Nasdaq: $IOVA)
    • MannKind Corporation (Nasdaq: $MNKD) Stock Hub
    • Microbot Medical Inc. (Nasdaq: $MBOT) Stock Hub
    • Moleculin Biotech (Nasdaq: $MBRX) Stock Hub
    • Novavax, Inc. (Nasdaq: $NVAX) Stock Hub
    • NRx Pharmaceuticals (Nasdaq: $NRXP) Stock Hub
    • Ocugen, Inc. (Nasdaq: $OCGN) Stock Hub
    • Ocular Therapeutix (Nasdaq: $OCUL) Stock Hub
    • Omeros Corporation (Nasdaq: $OMER): Stock Hub
    • Outlook Therapeutics (Nasdaq: $OTLK): Stock Hub
    • Protalix BioTherapeutics (NYSE American: $PLX) Stock Hub
    • SeaStar Medical Holding Corporation (Nasdaq: $ICU) Stock Hub
    • SELLAS Life Sciences Group (Nasdaq: $SLS) Stock Hub.
    • Summit Therapeutics (Nasdaq: $SMMT) Stock Hub
    • Travere Therapeutics (Nasdaq: $TVTX)
    • Viridian Therapeutics (Nasdaq: $VRDN)
  • FREE CATALYST CALENDAR
    • Catalyst Total Tracker
  • Merlintrader Travel Pub

Home - Weekly Reports - Wall Street weekly recap and next-week setup: why March 30–April 3 became a relief week

  • Weekly Reports

Wall Street weekly recap and next-week setup: why March 30–April 3 became a relief week

Executive summary The week that ended on Friday, April 3, was not a clean return to bullish calm. It was a relief week inside an unresolved macro problem. U.S. markets were closed on Good Friday, so the real trading week ended on Thursday, April 2. By then, the S&P 500 had posted a weekly gain and broken its five-week losing streak, while Wall Street had spent the entire week bouncing between fear of an extended energy shock and hope that the war-driven disruption around Iran and the Strait of Hormuz might not become a permanent economic wound.
2 months ago (Last updated: 2 months ago) 1 view
SPY chart
SPY static chart. Referral is applied only to the click, not to the image load.
Weekly Recap + Next Week Setup

Wall Street weekly recap and next-week setup: why March 30–April 3 became a relief week, why the oil shock still matters, and why April 6–10 could be the market’s first true inflation stress test

A broad and detailed market recap of the holiday-shortened week just ended, plus a forward-looking view of the macro events, earnings signals, sector shifts and tactical risks that can shape Wall Street in the week ahead.

Market week reviewed: March 30–April 3, 2026
Forward look: April 6–10, 2026
Focus: CPI, FOMC minutes, earnings, oil, positioning

What defined last week

The market finally stopped sliding. The S&P 500 snapped a five-week losing streak and the major indexes logged their strongest weekly gain in roughly four months, but the rebound was driven more by hopes of a geopolitical off-ramp than by a clean improvement in macro fundamentals.

What matters right now

Oil is still the transmission channel that matters most. The market recovered because traders started pricing the energy shock as temporary, yet front-month crude remained violently elevated and inflation risk has not gone away just because stocks bounced.

What will define next week

April 6–10 is about validation. If CPI comes in hot, if the Fed minutes sound uneasy, or if companies begin to talk about margin pressure from fuel, the relief rally could quickly turn back into a more defensive tape.

Executive summary

The week that ended on Friday, April 3, was not a clean return to bullish calm. It was a relief week inside an unresolved macro problem. U.S. markets were closed on Good Friday, so the real trading week ended on Thursday, April 2. By then, the S&P 500 had posted a weekly gain and broken its five-week losing streak, while Wall Street had spent the entire week bouncing between fear of an extended energy shock and hope that the war-driven disruption around Iran and the Strait of Hormuz might not become a permanent economic wound.

That distinction matters. Monday still looked fragile. The S&P 500 fell 0.39% and the Nasdaq dropped 0.73% as new warnings from Washington and a broader regional conflict kept inflation anxiety alive. Tuesday then became the key reversal day: all three major indexes posted their biggest one-day percentage gain since May 2025 as traders latched onto reports that the White House could accept an off-ramp even if the Strait remained only partially functional. Wednesday added another leg higher, powered by megacap technology, hopes of de-escalation and some selective risk appetite. Thursday was more cautious, but even a mixed close still left the week as the first positive one in six.

The underlying macro picture, however, did not fully improve. February JOLTS showed job openings down to 6.882 million and hiring at the lowest level since the pandemic era. ISM manufacturing for March rose to 52.7, which looked resilient on the surface, but supplier deliveries worsened and prices paid jumped to 78.3, the highest since June 2022. Then Friday’s jobs report, released while the stock market was closed, showed March payrolls rebounding by 178,000 versus the Reuters consensus of 60,000 and unemployment falling to 4.3%. That was strong enough to support the “Fed stays on hold” narrative, but not clean enough to erase concerns about revisions, labor-force softness and the inflation damage that high energy prices can still inflict over the next few months.

So the real message is simple. Last week bought the market time. It did not solve the market’s problem. April 6–10 now becomes the first real test of whether investors were right to treat the oil shock as temporary and earnings-manageable, or whether the next phase will be more uncomfortable once inflation data and corporate commentary start to catch up with reality.

Weekly scorecard — what the market just priced

ThemeWhat happenedWhy it mattered
Index actionThe S&P 500 broke a five-week losing streak and major indexes recorded their strongest weekly rise in four months.The market stopped free-falling, but the rebound came from reduced worst-case fear, not from a decisive macro all-clear.
OilFront-month crude remained highly volatile; on Thursday U.S. crude surged roughly 11% and Brent about 7%, while October Brent traded near $82.The curve signaled traders still expect disruption to be temporary, but near-term energy stress remains severe enough to pressure inflation, confidence and margins.
LaborJOLTS weakened, then payrolls rebounded sharply on Friday.The labor picture looks softer than it did a few months ago, but not weak enough yet to justify a clean recession call or fast Fed easing.
ManufacturingISM rose, but prices and delivery stress worsened.This is the classic uncomfortable mix: activity still alive, but cost pressure accelerating.
Rates narrativeMarkets have largely priced out rate cuts this year.That removes an important pillar that had supported bullish valuation frameworks earlier in the year.
PositioningMegacap tech and selected beta bounced hard on Tuesday and Wednesday.The tape is tradable, but still headline-sensitive and fragile if macro data turn against it.

What really happened during March 30–April 3

Monday, March 30: the week began with fear still in charge

Monday made clear that the market had not reached emotional equilibrium. The Dow managed a tiny gain, but the S&P 500 and Nasdaq closed lower as Washington’s messaging on Iran remained mixed and the conflict widened. Technology was among the biggest drags, with the semiconductor index falling 4.2%. The deeper message was not just that stocks were weak. It was that conviction was weak. Investors were trying to find a technical bottom in a tape still dominated by war headlines, inflation fears and uncertainty about how long the energy shock would last.

There was one stabilizing element. Jerome Powell said longer-term inflation expectations still appeared anchored and the Fed did not yet need to decide how to react. That helped prevent a worse session. Even so, money markets had already largely priced out any Fed easing this year, a remarkable shift from the rate-cut expectations that existed before the war and oil spike intensified.

Tuesday, March 31: the turning point of the week

Tuesday was the psychological center of the week. Reuters reported that the White House could be willing to accept an end to the military campaign even if the Strait of Hormuz was not fully reopened, and markets reacted as if they had been starved for exactly that kind of headline. The S&P 500 surged 2.91%, the Nasdaq rallied 3.83% and the Dow gained 2.49%, all their biggest one-day percentage gains since May 2025.

Importantly, this was not a narrow move. Nine of the 11 S&P sectors rose, led by communication services and technology. The chip index jumped 6.24%. Heavy volume confirmed that investors were actively re-risking, not just drifting higher on low participation. But the rally was still built on conditional optimism. It was a repricing of worst-case geopolitical assumptions, not proof that the economic damage had disappeared.

Wednesday, April 1: risk appetite broadened, but selectively

Wednesday extended the bounce. The S&P 500 rose another 0.72%, the Nasdaq 1.16% and the Dow 0.48%. Tech-heavyweights such as Alphabet, Meta and Amazon led, the semiconductor index rose again, and space names caught a speculative lift after Reuters reported that SpaceX had confidentially filed for an IPO. Planet Labs, Intuitive Machines and Rocket Lab were among the names that benefited from that spillover narrative.

This was also the day that confirmed what kind of rally this was: a relief move, not a broad macro-cleared advance. Investors bought duration-sensitive and momentum-heavy leadership because they believed the war might end sooner than feared and because the first-quarter drawdown had already reset some valuations. Reuters noted that the S&P 500 was then trading below 20 times expected earnings, its lowest multiple in ten months.

Thursday, April 2: calm at the close, but not real comfort

Thursday was a good reminder that the problem is still alive. Stocks opened lower after tougher rhetoric from President Trump and a violent move in front-month crude. U.S. crude jumped roughly 11% and Brent around 7% during the session, with Brent settling near $108. Yet equities clawed back much of the damage as the market focused on signs that Iran and Oman were discussing traffic management in the Strait and Britain was coordinating with other countries on crisis-resolution efforts.

The close was mixed rather than bullish. The Dow slipped 0.13%, while the S&P 500 gained 0.11% and the Nasdaq 0.18%. But the bigger signal came from the oil curve. October Brent near $82 suggested the market still believed the crisis would fade before autumn. In other words, the equity rebound and the shape of the oil market told the same story: investors are willing to look through today’s stress if they think it is not permanent.

Friday, April 3: the market was closed, but the macro tape kept moving

Friday’s payroll report mattered even without a cash-equity session. Nonfarm payrolls rose by 178,000 in March, far above the Reuters consensus of 60,000, while unemployment fell to 4.3%. Treasury yields rose, the dollar edged up and the immediate interpretation was straightforward: this report gives the Fed more room to wait.

That said, the number was not perfectly clean. February was revised to a larger decline of 133,000, and several strategists cited unusual labor-force movements and sector concentration in the hiring rebound. The practical conclusion is that the labor market is not collapsing, but it is not obviously pristine either. For stocks, that means the jobs report helped defend the soft-landing side of the argument, but it did not remove the inflation side of the problem.

Macro signals beneath the surface

JOLTS said the labor market had already been cooling

Before payrolls surprised higher, Tuesday’s JOLTS report told a softer story. Job openings fell by 358,000 to 6.882 million in February and hiring dropped to 4.849 million, the lowest since March 2020. That matters because openings and hiring often deteriorate before payrolls deliver a clearer message. It also fits the idea of a “low-hire, low-fire” labor market in which outright layoffs are not exploding, but companies are less eager to add staff.

ISM manufacturing looked stronger than it felt

Wednesday’s ISM manufacturing report landed at 52.7, the highest since August 2022. At first glance that looked like evidence that industrial activity was absorbing the shock. But the composition matters more than the headline. Supplier deliveries deteriorated and the prices-paid index surged to 78.3, the highest since June 2022. That is a warning sign. Sometimes a stronger PMI in a disrupted environment reflects not healthy demand, but scarcity, delays and pricing pressure.

The inflation problem has become simpler and more dangerous

The market now knows what the first inflation test is. Reuters’ poll for the March CPI report due on April 10 points to a 0.9% monthly increase in headline CPI and 0.3% in core. The reason this matters so much is not that one print decides the entire year. It matters because it will be the first broad inflation release to begin reflecting the gasoline surge and other direct energy effects from the war. If the headline is very hot, the market will not be able to dismiss it as stale information.

Main read-through: last week’s rally was built on the idea that the oil shock is temporary and economically survivable. Next week’s data can either reinforce that idea or begin to crack it. That is why CPI matters more than usual and why even “good” economic data can still be interpreted in a risk-negative way if they imply sticky inflation.

Sector and theme breakdown

Technology bounced because it had already been hit hard

The best-performing tape during the week was the same one that had been punished hardest in prior weeks: semis, megacap tech and selected high-beta growth. Tuesday and Wednesday showed that there is still a lot of money willing to re-enter these names as soon as the macro panic eases. That does not necessarily mean leadership is durable. It means positioning had gotten oversold enough that even a partial geopolitical relief story could trigger strong upside.

Energy still sets the tone even when energy stocks do not lead every day

An important nuance from the week is that crude remained the key macro variable even when energy equities were not always the best trade. On Tuesday the energy sector fell while the rest of the market rallied, because investors were betting on a future normalization in the physical oil story. This is exactly the kind of cross-current that matters now: the market may dislike expensive oil, but it can still buy equities if it believes the spike is temporary and the curve confirms that view.

Consumer discretionary remains vulnerable to margin and demand questions

Tesla’s weak quarter for deliveries and Nike’s sharp drop after warning on sales showed that the market is still ruthless with stories that combine cyclical exposure and imperfect execution. This is important for next week because if CPI is hot and fuel costs remain elevated, consumer-sensitive names will likely face a tougher discounting environment than balance-sheet-strong, cash-rich large caps.

Space and thematic beta woke up fast

Space stocks moved because the SpaceX IPO headline acted as a fresh narrative catalyst. These kinds of moves matter because they show that speculative appetite is not dead. It is dormant and selective. If macro stress eases further, these themes can continue to attract flows. But if the week ahead turns into an inflation scare, those same names can reverse just as quickly.

Why April 6–10 matters more than the rebound itself

The market has already done the first easy thing, which is bounce off fear. The harder part starts now. A relief rally can carry a market for a few sessions, but it does not automatically turn into a stable advance unless incoming data cooperate. Next week offers exactly the kind of sequence that can validate or damage the rebound.

Wednesday brings the minutes from the Fed’s March meeting. Thursday brings March CPI. Reuters also notes that another inflation indicator, the PCE release next week, will still mostly reflect February and therefore a period before the war’s full energy impact took hold. At the same time, earnings season starts to come into view, with Delta Air Lines and Constellation Brands due to report. Those numbers matter less for their own sake than for what they may say about fuel costs, demand sensitivity and pricing power.

In other words, next week is where the market has to move from headline-driven relief to evidence-driven conviction. If that evidence is mixed, the rally can survive but narrow. If that evidence turns ugly, especially on inflation, the market could discover that it has bounced faster than the underlying macro damage has healed.

Next week’s tactical calendar

DateEventWhy the market cares
Tuesday, April 7Post-holiday positioning and oil reactionAfter Good Friday and the jobs report, traders will have to reprice the labor surprise, yields and geopolitical headlines in a full cash session.
Wednesday, April 8FOMC minutesInvestors will look for how the Fed was thinking before the latest inflation wave and whether officials were already uncomfortable with energy-linked upside risk.
Thursday, April 9Delta Air Lines, Constellation Brands, early earnings toneUseful read-through on travel demand, consumer elasticity, fuel pressure and corporate language around the current macro backdrop.
Friday, April 10March CPIThe most important event of the week. Reuters’ poll points to +0.9% m/m headline CPI and +0.3% core, the first broad inflation reading likely to reflect part of the gasoline shock.

Three scenarios for the week ahead

Bull case

Oil stabilizes or drifts lower, the Fed minutes do not sound alarmed, and CPI is firm but not meaningfully worse than expected. In that setup the market can extend the relief rally, especially through quality growth, semiconductors and names that were punished hardest in March. The key to the bull case is not that everything improves. It is that nothing gets worse fast enough to break the fragile truce in sentiment.

Base case

The market chops around with a defensive undertone. CPI is hot on the headline but not shocking on core, earnings commentary is mixed, and oil remains volatile without breaking to a new panic high. In that environment the rebound survives, but leadership narrows, and the market becomes much more selective. Good balance sheets and credible earnings trajectories get rewarded; weak stories stop participating.

Bear case

CPI comes in hotter than expected, oil resumes climbing, and the first corporate reports start talking about a harder margin squeeze or more cautious demand trends. In that case last week’s rebound starts to look like a short-covering pause inside a broader repricing rather than the start of a durable recovery. The biggest risk is not simply lower indexes. It is a fast return to the harsher regime in which multiple compression and macro anxiety dominate everything else.

Bottom line

The most useful way to read last week is not “the market is fine again.” It is “the market was allowed to breathe.” That is better than another cascade lower, but it is not the same as resolution. Stocks rallied because the market chose to believe the oil shock is temporary and because incoming data, while mixed, were not disastrous enough to force a new panic immediately.

Now comes the harder part. April 6–10 will test whether that belief can survive contact with inflation data, Fed communication and the first hints from earnings season. If next week cooperates, the market can keep rebuilding from oversold conditions. If not, investors may discover that the bounce was real, but still incomplete.

Sources

Primary market and macro references used for this weekly update:

  • Reuters — Wall Street indexes mostly fall as Iran war widens (March 30, 2026)
  • Reuters — Wall Street soars as traders bet on potential war off-ramp (March 31, 2026)
  • Reuters — Wall Street ends higher on speculation about end to Iran war (April 1, 2026)
  • Reuters — Wall Street ends mixed as worries linger before Good Friday break (April 2, 2026)
  • Reuters — Instant View: U.S. jobs report for March is stronger than expected, likely keeping Fed on sidelines (April 3, 2026)
  • Reuters — U.S. job openings fall in February; hiring lowest since pandemic (March 31, 2026)
  • Reuters — U.S. manufacturing sector grows in March; supplier delivery performance deteriorates (April 1, 2026)
  • Reuters — Wall St Week Ahead: Inflation in focus for markets jostled by Middle East war signals (April 3, 2026)

Interpretive sections, scenario analysis and tactical framing reflect editorial judgment based on the sources above and are not statements of fact or investment advice.

Biotech Catalyst Calendar

Track upcoming FDA, trial and biotech market catalysts with the Merlintrader calendar.

Open the Biotech Catalyst Calendar

This content is for informational and educational purposes only and reflects editorial analysis, not personalized investment advice or a solicitation to buy or sell any security. Market conditions can change quickly, and some observations above are interpretive judgments rather than confirmed future outcomes.

For legal and site information, see the official Merlintrader disclaimer and terms/privacy pages.

Cosa ha definito la settimana

Il mercato ha finalmente smesso di scendere. Lo S&P 500 ha interrotto una striscia di cinque settimane negative e i principali indici hanno segnato la miglior performance settimanale da circa quattro mesi, ma il rimbalzo è stato guidato più dalla speranza di una via d’uscita geopolitica che da un vero miglioramento macro.

Cosa conta adesso

Il petrolio resta il canale di trasmissione più importante. Il mercato è risalito perché i trader hanno iniziato a prezzare lo shock energetico come temporaneo, ma il greggio front-month è rimasto estremamente volatile e il rischio inflazione non è sparito solo perché le azioni hanno rimbalzato.

Cosa definirà la prossima settimana

Il periodo 6–10 aprile è un test di conferma. Se il CPI uscirà caldo, se i verbali Fed suoneranno più nervosi del previsto, o se le aziende inizieranno a parlare di pressione sui margini da carburante, il relief rally potrebbe trasformarsi rapidamente di nuovo in un mercato difensivo.

Executive summary

La settimana conclusa venerdì 3 aprile non è stata un ritorno pulito alla serenità rialzista. È stata una settimana di sollievo dentro un problema macro ancora aperto. I mercati USA erano chiusi per il Good Friday, quindi la vera settimana di trading si è chiusa giovedì 2 aprile. A quel punto, lo S&P 500 aveva chiuso la settimana in rialzo interrompendo cinque settimane consecutive di perdite, mentre Wall Street aveva passato tutti i giorni oscillando tra paura di uno shock energetico prolungato e speranza che il disordine bellico legato all’Iran e allo Stretto di Hormuz non diventasse una ferita economica permanente.

Questa distinzione è fondamentale. Lunedì il mercato appariva ancora fragile. Lo S&P 500 ha perso lo 0,39% e il Nasdaq lo 0,73% mentre nuovi toni aggressivi da Washington e l’allargamento del conflitto regionale mantenevano viva l’ansia inflazionistica. Martedì è poi arrivata la giornata chiave di inversione: tutti e tre i principali indici hanno registrato la miglior seduta percentuale da maggio 2025 perché i trader si sono aggrappati alle indiscrezioni secondo cui la Casa Bianca poteva accettare una via d’uscita anche con lo Stretto solo parzialmente operativo. Mercoledì il rialzo è continuato, sostenuto dai megacap tech, dalle speranze di de-escalation e da un appetito per il rischio selettivo. Giovedì è tornata più cautela, ma anche una chiusura mista ha lasciato in eredità la prima settimana positiva in sei.

Il quadro macro sottostante, però, non è migliorato davvero in modo pulito. Il JOLTS di febbraio ha mostrato openings scese a 6,882 milioni e assunzioni ai minimi dal periodo pandemico. L’ISM manifatturiero di marzo è salito a 52,7, che in superficie sembra resiliente, ma consegne dei fornitori e prezzi pagati sono peggiorati nettamente, con il sottoindice prezzi salito a 78,3, massimo da giugno 2022. Poi venerdì, mentre il mercato azionario era chiuso, il jobs report ha mostrato payrolls di marzo in rialzo di 178.000 contro un consenso Reuters di 60.000, con disoccupazione scesa al 4,3%. Un dato abbastanza forte da rafforzare la narrativa “Fed ferma”, ma non abbastanza pulito da cancellare i dubbi su revisioni, fragilità della labor force e danno inflazionistico che energia alta può ancora trasmettere nei prossimi mesi.

Il vero messaggio, quindi, è semplice. La scorsa settimana ha comprato tempo al mercato. Non ha risolto il problema del mercato. Il 6–10 aprile diventa ora il primo vero test per capire se gli investitori avevano ragione nel trattare lo shock petrolifero come temporaneo e gestibile per gli utili, oppure se la prossima fase sarà più scomoda quando dati sull’inflazione e commenti aziendali inizieranno a rincorrere la realtà.

Scorecard settimanale — cosa ha prezzato il mercato

TemaCosa è successoPerché conta
IndiciLo S&P 500 ha spezzato una serie di cinque settimane negative e i principali indici hanno registrato il miglior rialzo settimanale da quattro mesi.Il mercato ha smesso di cadere a valanga, ma il rimbalzo è arrivato per riduzione della paura estrema, non per un chiaro “all clear” macro.
PetrolioIl crude front-month è rimasto violentemente volatile; giovedì il WTI è salito di circa l’11% e il Brent di circa il 7%, mentre il Brent di ottobre trattava vicino a 82 dollari.La curva segnala che i trader si aspettano una dislocazione temporanea, ma nel breve lo stress energetico resta abbastanza intenso da premere su inflazione, fiducia e margini.
LavoroIl JOLTS si è indebolito, poi i payrolls di venerdì hanno sorpreso al rialzo.Il quadro del lavoro appare più morbido rispetto a qualche mese fa, ma non ancora abbastanza debole da giustificare una chiamata recessiva pulita o tagli Fed rapidi.
ManifatturaL’ISM è salito, ma prezzi e stress sulle consegne sono peggiorati.È la miscela scomoda classica: attività ancora viva, ma pressione sui costi in accelerazione.
Narrativa sui tassiIl mercato ha quasi del tutto escluso tagli dei tassi nel 2026.Viene meno uno dei pilastri che aveva sostenuto i framework rialzisti di valutazione nella parte iniziale dell’anno.
PosizionamentoMegacap tech e beta selettivo hanno rimbalzato forte martedì e mercoledì.Il tape resta tradabile, ma ancora fragile e molto sensibile ai titoli macro.

Cosa è successo davvero tra il 30 marzo e il 3 aprile

Lunedì 30 marzo: la settimana è iniziata con la paura ancora al comando

Lunedì ha reso chiaro che il mercato non aveva ancora ritrovato equilibrio emotivo. Il Dow è riuscito a chiudere lievemente positivo, ma S&P 500 e Nasdaq hanno terminato in rosso mentre i messaggi da Washington sull’Iran restavano contraddittori e il conflitto si allargava. La tecnologia è stata tra i principali pesi, con l’indice dei semiconduttori in calo del 4,2%. Il messaggio profondo non era solo che le azioni fossero deboli. Era che fosse debole la convinzione. Gli investitori cercavano un bottom tecnico in un tape ancora dominato da guerra, inflazione e incertezza sulla durata dello shock energetico.

C’è stato comunque un elemento stabilizzante. Jerome Powell ha detto che le aspettative inflazionistiche di lungo termine sembravano ancora ancorate e che la Fed non aveva ancora bisogno di decidere come reagire ai nuovi problemi. Questo ha evitato una seduta peggiore. Nonostante ciò, il mercato monetario aveva già praticamente escluso tagli dei tassi per quest’anno, uno spostamento notevole rispetto alle attese pre-guerra e pre-impennata del petrolio.

Martedì 31 marzo: il vero turning point della settimana

Martedì è stato il centro psicologico della settimana. Reuters ha riportato che la Casa Bianca poteva essere disposta ad accettare la fine della campagna militare anche senza una riapertura completa dello Stretto di Hormuz, e il mercato ha reagito come se aspettasse proprio quel tipo di notizia. Lo S&P 500 è balzato del 2,91%, il Nasdaq del 3,83% e il Dow del 2,49%, tutti con la miglior seduta da maggio 2025.

Importante: non è stato un movimento ristretto a pochi nomi. Nove degli undici settori dello S&P hanno chiuso in rialzo, guidati da communication services e tecnologia. L’indice chip è salito del 6,24%. I volumi forti hanno confermato che gli investitori stavano davvero rimettendo rischio, non semplicemente lasciando salire i prezzi per inerzia. Ma il rally era comunque costruito su un ottimismo condizionale. Era un repricing degli scenari geopolitici peggiori, non la prova che il danno economico fosse sparito.

Mercoledì 1 aprile: l’appetito per il rischio si è allargato, ma in modo selettivo

Mercoledì il rimbalzo si è esteso. Lo S&P 500 ha aggiunto un altro 0,72%, il Nasdaq l’1,16% e il Dow lo 0,48%. I pesi massimi tech come Alphabet, Meta e Amazon hanno guidato, i semiconduttori sono saliti ancora, e i titoli space hanno preso una spinta speculativa dopo che Reuters ha riportato che SpaceX aveva presentato confidenzialmente documenti per una IPO. Planet Labs, Intuitive Machines e Rocket Lab sono stati tra i nomi che hanno beneficiato di questa narrativa di spillover.

Questa giornata ha confermato anche che tipo di rally fosse: un relief move, non un’avanzata ampia già ripulita da ogni rischio macro. Gli investitori hanno comprato leadership growth e duration-sensitive perché credevano che la guerra potesse finire prima del previsto e perché il drawdown del primo trimestre aveva già alleggerito alcune valutazioni. Reuters ha sottolineato che lo S&P 500 scambiava allora sotto 20 volte gli utili attesi, il multiplo più basso da dieci mesi.

Giovedì 2 aprile: chiusura calma, ma non vera serenità

Giovedì è stato un buon promemoria del fatto che il problema è ancora vivo. Le azioni hanno aperto in calo dopo toni più aggressivi di Trump e un movimento violentissimo del crude front-month. Il WTI è balzato di circa l’11% e il Brent di circa il 7% durante la sessione, con Brent in chiusura vicino a 108 dollari. Eppure gli indici hanno recuperato gran parte del danno perché il mercato si è concentrato sui segnali secondo cui Iran e Oman stavano discutendo la gestione del traffico nello Stretto e il Regno Unito coordinava altri Paesi per cercare una soluzione alla crisi.

La chiusura è stata mista, non rialzista in senso pieno. Il Dow ha perso lo 0,13%, mentre S&P 500 e Nasdaq hanno guadagnato rispettivamente lo 0,11% e lo 0,18%. Ma il segnale più importante arrivava dalla curva del petrolio. Un Brent di ottobre vicino a 82 dollari suggeriva che il mercato credesse ancora in una crisi destinata a sgonfiarsi prima dell’autunno. In altre parole, il rimbalzo azionario e la forma della curva petrolifera raccontavano la stessa storia: gli investitori sono disposti a guardare oltre lo stress attuale se pensano che non sia permanente.

Venerdì 3 aprile: mercato chiuso, ma il tape macro ha continuato a muoversi

Il jobs report di venerdì è stato importante anche senza cash session. I nonfarm payrolls sono saliti di 178.000 a marzo, ben sopra il consenso Reuters di 60.000, mentre la disoccupazione è scesa al 4,3%. I Treasury yield sono saliti, il dollaro ha guadagnato leggermente e l’interpretazione immediata è stata lineare: questo dato dà alla Fed più spazio per aspettare.

Detto questo, il numero non era perfettamente pulito. Febbraio è stato rivisto a un calo più marcato di 133.000 posti, e vari strategist hanno citato movimenti insoliti nella labor force e una concentrazione settoriale nella ripresa delle assunzioni. La conclusione pratica è che il mercato del lavoro non sta collassando, ma non è nemmeno ovviamente perfetto. Per le azioni questo significa che il jobs report ha aiutato a difendere la narrativa soft landing, senza però rimuovere il lato inflattivo del problema.

Segnali macro sotto la superficie

Il JOLTS diceva che il lavoro stava già rallentando

Prima del jobs report sorprendentemente forte, il JOLTS di martedì raccontava una storia più morbida. Le job openings di febbraio sono scese di 358.000 unità a 6,882 milioni e le assunzioni sono calate a 4,849 milioni, minimo da marzo 2020. Questo conta perché openings e hiring spesso si deteriorano prima che i payrolls mandino un messaggio più chiaro. Si inserisce anche bene nell’idea di un mercato del lavoro “low-hire, low-fire”, dove i licenziamenti non esplodono, ma le aziende sono meno propense ad assumere.

L’ISM manifatturiero sembrava più forte di quanto fosse davvero

L’ISM manifatturiero di mercoledì si è attestato a 52,7, massimo da agosto 2022. A prima vista sembrava la prova che l’industria stesse assorbendo lo shock. Ma conta più la composizione del headline. Le consegne dei fornitori sono peggiorate e il sottoindice prezzi pagati è balzato a 78,3, massimo da giugno 2022. È un campanello d’allarme. In ambienti disturbati, un PMI più forte può riflettere non una domanda sana, ma scarsità, ritardi e pressione sui prezzi.

Il problema inflazione ora è più semplice e più pericoloso

Il mercato sa ormai qual è il primo vero test sull’inflazione. Il sondaggio Reuters per il CPI di marzo, in uscita il 10 aprile, punta a un +0,9% mensile sul headline e +0,3% sul core. Il motivo per cui conta così tanto non è che un singolo dato decida tutto l’anno. Conta perché sarà il primo dato inflazionistico ampio a iniziare a riflettere il balzo della benzina e altri effetti diretti dell’energia legati alla guerra. Se il dato headline uscirà molto caldo, il mercato farà più fatica a liquidarlo come informazione già vecchia.

Lettura chiave: il rally della scorsa settimana è stato costruito sull’idea che lo shock petrolifero sia temporaneo e economicamente sopportabile. I dati della prossima settimana possono rafforzare questa idea oppure iniziare a incrinarla. Per questo il CPI conta più del solito e per questo anche dati “buoni” sull’economia possono essere letti in modo risk-negative se implicano inflazione ancora appiccicosa.

Scomposizione per settori e temi

La tecnologia è rimbalzata perché era già stata colpita duramente

Il tape migliore della settimana è stato lo stesso che aveva sofferto di più nelle settimane precedenti: semiconduttori, megacap tech e growth a beta elevato. Martedì e mercoledì hanno mostrato che c’è ancora molto denaro pronto a rientrare su questi nomi appena la paura macro si allenta. Questo non significa necessariamente che la leadership sia già duratura. Significa che il posizionamento era diventato abbastanza oversold da permettere un rialzo forte anche solo con una narrativa geopolitica meno estrema.

L’energia continua a dare il tono anche quando i titoli energy non guidano ogni seduta

Una sfumatura importante della settimana è che il crude è rimasto la variabile macro chiave anche quando le energy equities non erano il trade migliore ogni giorno. Martedì il settore energia è sceso mentre il resto del mercato saliva, perché gli investitori stavano scommettendo su una futura normalizzazione del petrolio fisico. È esattamente il tipo di cross-current che conta ora: il mercato può non amare il petrolio caro, ma può comunque comprare azioni se crede che il picco sia temporaneo e la curva lo confermi.

I consumer discretionary restano vulnerabili a margini e domanda

Il trimestre debole di Tesla sulle consegne e il tonfo di Nike dopo il warning sulle vendite hanno mostrato che il mercato resta spietato con le storie che combinano esposizione ciclica ed execution imperfetta. Questo è importante per la prossima settimana perché, se il CPI uscirà caldo e i costi carburante resteranno elevati, i nomi più sensibili ai consumi potrebbero affrontare un contesto di sconto molto più duro rispetto ai large cap con cassa forte e bilanci solidi.

Lo space ha riacceso il beta tematico molto in fretta

I titoli space si sono mossi perché la notizia su SpaceX IPO ha agito da catalizzatore narrativo fresco. Questi movimenti contano perché mostrano che l’appetito speculativo non è morto. È dormiente e selettivo. Se lo stress macro dovesse allentarsi ancora, questi temi potrebbero continuare ad attrarre flussi. Ma se la settimana entrante dovesse trasformarsi in un nuovo shock inflazionistico, gli stessi nomi possono invertire rapidamente.

Perché il 6–10 aprile conta più del rimbalzo stesso

Il mercato ha già fatto la prima cosa facile, cioè rimbalzare dalla paura. La parte difficile inizia adesso. Un relief rally può trascinare gli indici per qualche seduta, ma non si trasforma automaticamente in un advance stabile se i dati in arrivo non collaborano. La prossima settimana offre proprio la sequenza che può validare o rovinare il rimbalzo.

Mercoledì arrivano i verbali della riunione Fed di marzo. Giovedì e venerdì si entra nel cuore del test inflattivo e nel primo tono della stagione utili, con Reuters che segnala CPI di marzo e i primi report di aziende come Delta Air Lines e Constellation Brands. Questi numeri contano meno per il singolo titolo e più per ciò che possono dire su costi del carburante, sensibilità della domanda e pricing power.

In altre parole, la prossima settimana è il punto in cui il mercato deve passare dal relief guidato dai titoli alla convinzione guidata dalle evidenze. Se queste evidenze saranno miste, il rally può sopravvivere ma restringersi. Se invece si deteriorano, soprattutto sul fronte inflazione, il mercato potrebbe scoprire di aver rimbalzato più velocemente di quanto il danno macro reale si sia rimarginato.

Calendario tattico della prossima settimana

DataEventoPerché il mercato guarda
Martedì 7 aprileRepricing post-festivo e reazione al petrolioDopo Good Friday e il jobs report, i trader dovranno riprezzare la sorpresa sul lavoro, i Treasury yield e i titoli geopolitici in una vera cash session.
Mercoledì 8 aprileVerbali FOMCGli investitori cercheranno indizi su come la Fed ragionava prima dell’ultima ondata inflattiva e se i membri erano già a disagio con il rischio energia.
Giovedì 9 aprileDelta Air Lines, Constellation Brands, prime indicazioni utiliRead-through utile su domanda travel, elasticità dei consumi, pressione carburante e linguaggio aziendale sul contesto macro attuale.
Venerdì 10 aprileCPI di marzoL’evento più importante della settimana. Il sondaggio Reuters punta a +0,9% m/m sul CPI headline e +0,3% sul core, primo dato ampio che dovrebbe riflettere almeno in parte lo shock benzina.

Tre scenari per la settimana in arrivo

Scenario bull

Il petrolio si stabilizza o scende, i verbali Fed non suonano allarmati e il CPI è forte ma non molto peggiore delle attese. In questo setup il mercato può estendere il relief rally, soprattutto tramite quality growth, semiconduttori e nomi colpiti più duramente a marzo. La chiave dello scenario bull non è che tutto migliori. È che nulla peggiori abbastanza velocemente da rompere la fragile tregua del sentiment.

Scenario base

Il mercato si muove in modo laterale con tono difensivo. Il CPI esce caldo sull’headline ma non scioccante sul core, i commenti societari sono misti e il petrolio resta volatile senza spingersi verso nuovi picchi di panico. In questo contesto il rimbalzo sopravvive, ma la leadership si restringe e il mercato diventa molto più selettivo. I bilanci forti e i percorsi utili credibili vengono premiati; le storie deboli smettono di partecipare.

Scenario bear

Il CPI esce più caldo del previsto, il petrolio riprende a salire e le prime aziende iniziano a parlare di squeeze più duro sui margini o di domanda più cauta. In quel caso il rimbalzo della settimana passata inizia a somigliare più a una pausa da short covering dentro un repricing più ampio che all’inizio di un recupero duraturo. Il rischio maggiore non è solo vedere indici più bassi. È il ritorno rapido a un regime più duro in cui compressione dei multipli e ansia macro dominano tutto il resto.

Bottom line

Il modo più utile per leggere la settimana passata non è “il mercato sta di nuovo bene”. È “al mercato è stato concesso di respirare”. È meglio di un’altra gamba violenta al ribasso, ma non equivale a una risoluzione del problema. Le azioni hanno rimbalzato perché il mercato ha scelto di credere che lo shock petrolifero sia temporaneo e perché i dati in arrivo, pur misti, non sono stati abbastanza brutti da forzare un nuovo panico immediato.

Adesso arriva la parte difficile. Il 6–10 aprile testerà se questa convinzione può sopravvivere al contatto con dati sull’inflazione, comunicazione Fed e primi segnali dalla earnings season. Se la prossima settimana collaborerà, il mercato potrà continuare a ricostruire da condizioni oversold. Se non lo farà, gli investitori potrebbero scoprire che il rimbalzo era reale, ma ancora incompleto.

Sources

Principali riferimenti di mercato e macro usati per questo weekly update:

  • Reuters — Wall Street indexes mostly fall as Iran war widens (30 marzo 2026)
  • Reuters — Wall Street soars as traders bet on potential war off-ramp (31 marzo 2026)
  • Reuters — Wall Street ends higher on speculation about end to Iran war (1 aprile 2026)
  • Reuters — Wall Street ends mixed as worries linger before Good Friday break (2 aprile 2026)
  • Reuters — Instant View: U.S. jobs report for March is stronger than expected, likely keeping Fed on sidelines (3 aprile 2026)
  • Reuters — U.S. job openings fall in February; hiring lowest since pandemic (31 marzo 2026)
  • Reuters — U.S. manufacturing sector grows in March; supplier delivery performance deteriorates (1 aprile 2026)
  • Reuters — Wall St Week Ahead: Inflation in focus for markets jostled by Middle East war signals (3 aprile 2026)

Le parti interpretative, gli scenari e l’inquadramento tattico riflettono un giudizio editoriale basato sulle fonti sopra e non costituiscono fatti certi sul futuro né consulenza finanziaria.

Biotech Catalyst Calendar

Segui i prossimi catalyst biotech, FDA e trial con il calendario Merlintrader.

Apri il Biotech Catalyst Calendar

Questo contenuto è fornito solo a scopo informativo ed educativo e rappresenta analisi editoriale, non consulenza finanziaria personalizzata né sollecitazione all’acquisto o alla vendita di strumenti finanziari. Le condizioni di mercato possono cambiare rapidamente e alcune osservazioni sopra sono valutazioni interpretative, non esiti confermati.

Per informazioni legali e di sito, consultare il disclaimer ufficiale Merlintrader e le pagine termini/privacy.

What do you feel about this?

  • Weekly Reports

Post navigation

Previous: Cannabis policy 2026: what Schedule III could really change
Next: Viridian Therapeutics (VRDN): after the crash, what still matters now?

Related Stories

weekly 25-29 may
  • Weekly Reports

Weekly Market Recap & Outlook for May 25–29, 2026: Memorial Day, Iran/Hormuz, Warsh Fed, Core PCE and the AI Earnings Test

3 weeks ago 0
weekly april 25
  • Weekly Reports

Wall Street weekly recap and next-week setup april27-2026 ( $SPY )

2 months ago 1
  • Weekly Reports

Wall Street weekly recap and next-week setup: why April 6–10 became the market’s strongest week since November

2 months ago 0
  • Weekly Reports

Wall Street weekly recap ($SPY) and next-week setup – March 30–April 3

3 months ago 0
  • Weekly Reports

Weekly recap and next-week setup March 23–27

3 months ago 0
  • Weekly Reports

Weekly Market Recap & Next Week Prep — March 15, 2026

3 months ago 0

Trending Now

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial AMLX 1
  • Reports Biotech

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial

37 minutes ago 35
The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL The week ahead jun 15 2
  • Editorial

The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL

3 hours ago 31
Short Squeeze Watch: three crowded short-interest stocks, but not the same setup Short 3
  • Uncategorized

Short Squeeze Watch: three crowded short-interest stocks, but not the same setup

2 days ago 11
FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions UNCY SPRO CAPR 4
  • Reports Biotech

FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions

2 days ago 16

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.
✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →
✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.
✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.
```
Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

  • Full reports on individual stocks
  • FDA, catalyst and clinical-trial analysis
  • Daily briefings, watchlists and market themes
  • A free archive updated on a regular basis
Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

  • Report completi su singoli titoli
  • Analisi di catalyst, FDA e trial clinici
  • Daily briefing, watchlist e temi di mercato
  • Un archivio gratuito aggiornato con regolarità
Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Merlintrader Newsletter

Stay ahead of the next catalyst

Get market notes, deep-dive updates and catalyst-focused research directly from Merlintrader.

Educational market content only. No spam. You can unsubscribe anytime.
Terms, privacy and disclaimer

You May Have Missed

AMLX
  • Reports Biotech

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial

37 minutes ago 35
The week ahead jun 15
  • Editorial

The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL

3 hours ago 31
Short
  • Uncategorized

Short Squeeze Watch: three crowded short-interest stocks, but not the same setup

2 days ago 11
UNCY SPRO CAPR
  • Reports Biotech

FDA Pressure Builds Into Summer: Unicycive, Spero and Capricor Move Toward High-Stakes Decisions

2 days ago 16

Scanner for active traders
ChartsWatcher logo

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

ChartsWatcher platform screenshot
Recommended platform
Medved Trader logo

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Medved Trader platform dashboard
Monica.im Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Merlintrader author

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

The full texts of the disclaimers and terms of use, in both Italian and English, are available on the official Merlintrader legal pages listed below.

Donate via PayPal

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Buy Me a Coffee

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

  • Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
  • ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
  • Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
  • Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
  • Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
  • Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

Some of the links above are affiliate links. If you decide to subscribe or purchase through them, it may generate a small commission for Merlintrader at no extra cost to you. This helps keep the site online and the reports freely accessible. You are under no obligation to use these links; always choose the solution that best fits your needs and your own evaluation.

Full legal information, risk warnings and terms of use are available on the official Merlintrader legal pages:

Disclaimer and risk warnings | Terms of use and privacy information

The same pages also include the corresponding English text or an English equivalent of the main legal notices, so that international readers can access the core risk disclosures and terms of use.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

Terms and Conditions
Cookie Policy
Privacy Policy
Merlintrader is a personal blog curated by Horacio F. Greco. Contact: info@merlintrader.com. No professional financial advice.
Do Not Sell or Share My Personal Information
  • Policies, Terms and Conditions
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Voce di menu
  • Our Profile on PRLog
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.